See every side of every news story
Get Started
SubscribeLogin
Donald Trump
Everton
Volodymyr Zelenskyy
Ukraine War
Hamas
Viktor Orbán
Basketball
Israel-Hamas Conflict
Elon Musk
Javier Milei
Manchester United
Vladimir Putin
Published • loading... • Updated

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

Summary by Cryptocurrency News | Cryptocurrency Prices | Market Cap
Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further analysis and discussions on …

6 Articles

All
Left
Center
Right
hcplive.comhcplive.com

SPN-820 Fails Phase 2b Trial for Treatment-Resistant Depression

A phase 2b trial showed that, unlike patients with MDD, patients with treatment-resistant depression do not receive significant benefits from SPN-820.

Read Full Article
psychiatrictimes.compsychiatrictimes.com

SPN-820 Fails to Meet Primary Endpoint in Study of Adults with Treatment-Resistant Depression

After a lot of recent positive news for SPN-820, a recent phase 2b study shows the novel antidepressant failed to demonstrate a statistically significant improvement on the primary endpoint of change from baseline.

Read Full Article
Cryptocurrency News | Cryptocurrency Prices | Market CapCryptocurrency News | Cryptocurrency Prices | Market Cap

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further analysis and discussions on …

Read Full Article
pharmaceutical-technology.compharmaceutical-technology.com

Supernus’s stock sinks after depression drug fails trial - Pharmaceutical Technology

The Phase IIb trial missed its primary endpoint in patients with treatment-resistant depression.

Read Full Article
PharmaphorumPharmaphorum

Supernus reports less than super data for depression drug

Supernus Pharma has suffered a blow to its R&D pipeline after a candidate for treatment-resistant depression failed a phase 2b trial

Read Full Article
Endpoints NewsEndpoints News

Supernus’ stock sinks after placebo effect derails mid-stage depression study

The risk of drug development in the neuropsychiatric field is that the drug may work — but sometimes placebo does too. Supernus Pharmaceuticals became the latest casualty of this when it

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Endpoints News broke the news in on Wednesday, February 19, 2025.
Sources are mostly out of (0)

Similar News Topics

News
For You
Search
BlindspotLocal